Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms — Physician’s First Watch
Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms
By Joe Elia
Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a joint statement from the U.S. Food and Drug Administration and the European Medicines Agency.
The drugs were the subject of a JAMA Internal Medicine study in 2013 that linked their use to a doubled risk for hospitalization for acute pancreatitis.
In the New England Journal of Medicine, the agencies say that they have separately "explored multiple streams of data" and that assertions of a link between the drugs and pancreatic side effects "are inconsistent with the current data." However, they also write that "the FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship."